1-3 of 3
Leo Ruhnke
Close
Sort by
Journal Articles

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse

Clinical Trials & Observations
Andrew F. Berdel, Leo Ruhnke, Linus Angenendt, Martin Wermke, Christoph Röllig, Jan-Henrik Mikesch, Annika Scheller, Teresa Hemmerle, Mattia Matasci, Klaus Wethmar, Torsten Kessler, Mirjam Gerwing, Daniel Hescheler, Michael Schäfers, Wolfgang Hartmann, Bianca Altvater, Claudia Rossig, Martin Bornhäuser, Georg Lenz, Matthias Stelljes, Bjoern Rueter, Dario Neri, Wolfgang E. Berdel, Christoph Schliemann
Journal: Blood Advances
Blood Adv (2022) 6 (12): 3684–3696.
https://doi.org/10.1182/bloodadvances.2021006909
Published: 2022
Includes: Supplemental data
Journal Articles

Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment

Clinical Trials & Observations
Raphael Teipel, Frank Kroschinsky, Michael Kramer, Theresa Kretschmann, Katharina Egger-Heidrich, Thomas Krüger, Leo Ruhnke, Sylvia Herold, Sebastian Stasik, Katja Sockel, Jan M. Middeke, Karolin Trautmann-Grill, Martin Bornhäuser, Christian Thiede, Malte von Bonin
Journal: Blood Advances
Blood Adv (2022) 6 (6): 1941–1946.
https://doi.org/10.1182/bloodadvances.2021005747
Published: 2022
Includes: Supplemental data
Journal Articles

The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemia

Clinical Trials & Observations
Vladan Vucinic, Leo Ruhnke, Katja Sockel, Maximilian Alexander Röhnert, Donata Backhaus, Dominic Brauer, Georg-Nikolaus Franke, Dietger Niederwieser, Martin Bornhäuser, Christoph Röllig, Uwe Platzbecker, Sebastian Schwind, Madlen Jentzsch
Journal: Blood Advances
Blood Adv (2021) 5 (24): 5584–5587.
https://doi.org/10.1182/bloodadvances.2021005974
Published: 2021
Includes: Supplemental data